Company Overview of Target Discovery, Inc.
Target Discovery, Inc. discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and management of disease. The company focuses on isoforms protein biomarkers and diagnostics for cancer. It develops and commercializes Isonostic products that include Isonostic assays for the monitoring and treatment of prostate, breast, and ovarian cancer. Target Discovery, Inc. was founded in 1999 and is headquartered in Palo Alto, California.
4030 Fabian Way
Palo Alto, CA 94303-4607
Founded in 1999
Key Executives for Target Discovery, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Target Discovery, Inc., please visit www.targetdiscovery.com. Company data is provided by Capital IQ. Please use this form to report any data issues.